KR20230069631A - Pharmaceutical Composition for Preventing or Treating Sarcopenia Comprising Steamed Mature Silkworm Products having Silk Protein - Google Patents

Abstract

The present invention relates to a composition for preventing or treating sarcopenia, comprising a cooked silkworm-processed product containing a silk protein. The cooked silkworm-processed product containing a silk protein, according to the present invention, shows effects of excellent weight gain, muscle strength improvement, muscle weight increase and/or memory improvement in a sarcopenia model, thus can be used as a composition for preventing, treating, and alleviating sarcopenia. In addition, it is expected that various health supplements or medicines would be developed and sold by using active ingredients of the present invention. Therefore, it is expected that the present invention would show effects of contributing to developing sericulture industry by creating usability and added value of cooked silkworm-processed products having silk glands. Additionally, it is expected to greatly contribute to reducing soaring social costs such as health care costs, and the like due to sarcopenia and various adult diseases caused thereby and improving life quality of people.

Description

Composition for preventing or treating sarcopenia containing cooked silkworm products containing silk protein

The present invention relates to a composition for the prevention or treatment of sarcopenia comprising a cooked silkworm product containing silk protein, and more specifically, raw silkworms selected from silkworms from the 5th day of age to 4th day of age to the ripening stage are put in water and cooked. Or, it relates to a composition for preventing or treating sarcopenia, comprising a processed silkworm product containing silk protein, cooked with the heat of steam.

Due to the development of medical technology and the improvement of personal hygiene, life expectancy is rapidly increasing, and in 2020, the elderly population over 65 years old is 8,134,674, accounting for 16.5% of the total population. In addition, a large number of older people (27.7% of older males and 24.3% of females) suffer from geriatric sarcopenia, characterized by loss of skeletal muscle and weight loss. Such senile sarcopenia or muscle weakness is clinically observed when very low muscle mass is observed due to abnormal degeneration and death of muscle cells regardless of nutrition intake, when it occurs due to imbalance in nutritional intake and lack of exercise, and degenerative There are cases where secondary diseases develop as a result of the progression of diseases such as metabolic diseases, cancers, and neurological diseases.

More specifically, sarcopenia is one of the representative intractable diseases, the cause of which has not yet been identified, caused by degeneration of spinal nerves, motor nerves, or skeletal muscle fibers, and is a degenerative disease in which muscle mass and strength decrease, Unlike muscle loss that occurs during the normal aging process, it refers to a disease in which muscle mass is abnormally and rapidly reduced. Individuals suffering from sarcopenia have significantly reduced muscle mass, motor power, and muscle strength, making it difficult to live independently, and have high mortality rates because it is difficult to improve from other diseases such as brain disease, heart disease, and diabetes. This sarcopenia is divided into primary sarcopenia due to aging and secondary sarcopenia caused by various causes. Inflammation, malignant disease, or endocrine metabolic disease.

Primary sarcopenia, also called age-related sarcopenia, is known to occur as the number and differentiation capacity of adult muscle stem cells, known as satellite cells, gradually decrease with age (Gabi Shefer et al., Developmental Biology , 2006). In other words, geriatric sarcopenia is a disease that occurs due to a decrease in the differentiation potential of myoblasts in aging individuals, and is a neuromuscular disease that occurs when nerve cells that control autonomic muscles are damaged, such as muscle dystrophy, neuromuscular junction disease, and motor neuron disease. The families differ in pathogenesis and treatment methods.

In modern Korean society, the elderly population is rapidly increasing due to the increase in life expectancy, and the proportion of elderly people living independently is very high due to nuclear families and declining birth rates, so medical and social costs due to geriatric sarcopenia are expected to increase. However, due to the complex etiology of sarcopenia, an effective treatment target has not been identified so far, and there is no effective treatment, so it is treated with active nutritional supplementation and exercise therapy. Therefore, it is necessary to develop an effective therapeutic agent by identifying the mechanism of senile sarcopenia, discovering an effective treatment target, and screening a drug using the same.

According to studies so far, skeletal muscle contraction does not progress because motor nerves that induce skeletal muscle contraction are degenerated, or the expression of proteins involved in muscle contraction is reduced in skeletal muscle, or the protein is modified to normal contraction of skeletal muscle. This does not progress, and in the long term, it is known that the motor nerve or skeletal muscle is transformed into fibrous tissue. Since the fundamental cause of sarcopenia has not yet been identified, and a method for preventing or recovering the degeneration of motor neurons or skeletal muscles has not been developed, it is currently difficult to develop a method for slowing the progression of sarcopenia. Research is actively under way.

Currently, as a method of treating sarcopenia, a method of suppressing muscular atrophy caused by degeneration or progressive mutation of muscle cells, which is a type of sarcopenia, is mainly used. For example, WO 2007/088123 discloses a treatment for muscular dystrophy containing a nitroxy derivative as an active ingredient, and WO 2006/081997 discloses a treatment for muscular dystrophy containing atraric acid or a derivative thereof as an active ingredient.

However, since these therapeutic agents containing the compound as an active ingredient act not only on the skeletal muscle with muscular dystrophy, but also on the visceral muscle or myocardium not related to muscular dystrophy, they can cause various side effects, large and small, and have not been used for practical treatment. .

Therefore, it is necessary to develop a new sarcopenia treatment that can effectively reduce only sarcopenia while ingesting herbal medicines derived from natural products without side effects in the form of common foods, rather than artificially used treatments.

On the other hand, the sericulture industry that produces silkworm cocoons is a traditional Korean industry that has been continued since the Gojoseon Dynasty. In the 1970s, more than 1 million boxes of silkworms were raised in farms annually, but it is currently in a state of great decline due to economic development and the influence of high-quality chemical fibers. . Accordingly, the current sericulture industry has shifted to an industry that produces health functional food ingredients such as dried silkworms, male pupae, and cordyceps. The reason why 5 instar 3-day dried silkworms are used is that from the 5th instar 4th day after the 5th instar 3 days, the strong silk protein rapidly enlarges in the body of the silkworm, making it very difficult to use for food. The silk protein is stored in the silkworm's body in the form of a silk thread, and when the silkworm becomes a grown-up silkworm (mature silkworm), it spits out the silk protein and builds a silkworm cocoon, a raw material for silk.

In this way, silkworms that have passed the edible period are not used in any special way other than for the production of silk, and in research on silkworm-related medicines, only studies related to silk peptides are being conducted. Studies using silkworms (or silkworms) containing protein are incomplete, and most of the conventional methods of utilizing silkworms are not using all useful active substances contained in silkworms together, but only simple silkworm cocoons made of silk protein. When hydrolyzing silkworm cocoons for silkworms, there is a problem of high cost and loss of useful components. In order to solve this problem, it is necessary to use all the ingredients contained in silkworm together with silk protein.

Therefore, since cooked silkworm containing silk protein is a biocompatible and safe natural material, it can be applied as a therapeutic agent for treating sarcopenia and related diseases.

1. Korean Patent Registration No. 10-1388455 (Title of Invention: Silkworm Processing Method with Silk Protein and Processed Silkworm Products) 2. Korean Patent Registration No. 10-1546446 (Title of Invention: Health functional food and cosmetic composition containing silkworm processed product containing silk protein)

Under these circumstances, the present inventors have made diligent efforts to develop a therapeutic agent for sarcopenia that is excellent and safe for the human body. As a result, the present inventors found that the cooked silkworm product (cooked sookjam; Hongjam) containing silk protein significantly increased weight, increased muscle weight, increased muscle strength, improved exercise ability, improved postural control ability, The present invention was completed by clarifying that spatial memory enhancement and social memory enhancement effects could be achieved.

Accordingly, one object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of sarcopenia comprising a silk protein-containing processed silkworm product as an active ingredient.

In addition, another object of the present invention is to provide a food composition or health functional food for preventing or improving sarcopenia, including a cooked silkworm product containing silk protein.

In addition, another object of the present invention is to provide a feed feed additive or feed composition for preventing or improving sarcopenia in animals, including a cooked silkworm product containing silk protein.

Another object of the present invention is to provide a method for treating sarcopenia comprising administering a composition comprising a silk protein-containing cooked silkworm product to a non-human subject.

The terms used herein are used for descriptive purposes only and should not be construed as limiting. Singular expressions include plural expressions unless the context clearly dictates otherwise. In this specification, terms such as "include" or "have" are intended to designate that there is a feature, number, step, operation, component, part, or combination thereof described in the specification, but one or more other features It should be understood that the presence or addition of numbers, steps, operations, components, parts, or combinations thereof is not precluded.

Unless defined otherwise, all terms used herein, including technical or scientific terms, have the same meaning as commonly understood by a person of ordinary skill in the art to which the embodiment belongs. Terms such as those defined in commonly used dictionaries should be interpreted as having a meaning consistent with the meaning in the context of the related art, and unless explicitly defined in the present application, they should not be interpreted in an ideal or excessively formal meaning. don't

Hereinafter, the present invention will be described in more detail.

According to one aspect of the present invention, the present invention provides a pharmaceutical composition for preventing or treating sarcopenia, comprising a silk protein-containing processed silkworm product as an active ingredient.

The processed silkworm product of the present invention is prepared by cooking raw silkworms in water or by steaming, and is characterized in that it can be consumed as a food while containing all of the silk protein.

In this specification, the word "cooked silkworm" used while referring to the active ingredient is used interchangeably with cooked sokjam or hongjam within the specification.

Conventionally, health functional foods using silkworms or silk peptides have been used in various ways in the art, but it is clear that the ingredients of silk peptides and the ingredients of silkworms are different. It is confirmed that the content of the components contained in is different.

Therefore, silkworms having silk proteins, which were previously inedible and had no use other than breeding to make cocoons for silk production, are processed into a state that can be consumed for dietary use containing silk protein to prevent sarcopenia or The significance of the present invention is that it can be used as a material for a therapeutic composition.

Accordingly, the present invention is to provide a composition for preventing or treating sarcopenia containing cooked silkworm products containing silk protein as an active ingredient and a health functional food containing the same, and as a specific example, the silk protein containing Various effects on cooked silkworm products, that is, the results of confirming that the cooked silkworm products also exhibit effects of increasing body weight, increasing muscle weight, increasing muscle strength, enhancing exercise capacity, improving posture control ability, enhancing spatial memory, and/or increasing social memory Based on this, the cooked silkworm product containing the silk protein can be applied as an active ingredient of a composition for preventing or treating sarcopenia, particularly, a composition for preventing or treating senile sarcopenia, or a food composition containing the same.

In the present invention, the term "sarcopenia" refers to a disease in which muscle volume and muscle strength gradually decline, and due to a decrease in skeletal muscle mass, directly causes a decrease in muscle strength, resulting in a decrease in various physical functions and It is known to cause disability and increase the risk of death. It is a disease that appears as a result of the gradual decline of skeletal muscle associated with aging.

The sarcopenia may be at least one selected from the group consisting of muscular dystrophy, myasthenia gravis, muscular dystrophy, myasthenia gravis, hypotonia, muscle weakness, muscular dystrophy, amyotrophic lateral sclerosis, and myasthenia gravis.

In particular, the cooked silkworm product containing the silk protein of the present invention has therapeutic and preventive effects on sarcopenia by specifically inhibiting the decrease in muscle mass.

In the present specification, the cooked silkworm product containing the silk protein refers to a product manufactured through the process of cooking all silkworms, such as 3 sleep, 4 sleep, etc. It is possible to select and use any one or more of the silkworms up to the sleeping period, and it is best to use silkworms in the sleeping period more preferably. This is because silkworms can be used for silkworms aged 5 days and 3 days, but silkworms have less silk protein than silkworms aged 5 days and 4 days, so there is a concern that the present invention may not sufficiently exhibit the desired efficacy.

On the other hand, the silkworm in the sleeping period means a silkworm full of silk protein in the body of the silkworm before it builds a cocoon. It is most suitable for use as an active ingredient in health functional foods).

In the present invention, in order to make all of the silk protein contained in silkworms edible, the silkworms are processed and prepared in the form of a processed product, and used as an active ingredient in a pharmaceutical composition or food composition (health functional food).

The cooked silkworm product, which is the active ingredient, is prepared by putting raw silkworms selected from silkworms from 4 days old to 4 days old in water at a temperature of 55 to 125 ° C for 30 minutes to 24 hours, or by steam heat. It is prepared by cooking, and preferably, the silkworm is cooked for 100 to 150 minutes with heat of steam at 80 to 125 ° C., so that all silk proteins are contained. That is, when manufacturing for more than 150 minutes with steam heat of less than 80 ° C, the manufacturing time is too long, and there is a risk of destroying the active ingredients of the silkworm itself, including silk protein, and less than 100 minutes in excess of 125 ° C. In the case of manufacturing, the temperature is too high, and this is also because there is a risk of adversely affecting the active ingredients of the silkworm itself containing silk protein.

After the above-cooked process, it can be dried by a conventional method and used in powder form. Preferably, it is good to dry it through any one selected from hot air drying or vacuum freeze drying and pulverize it, and to reduce the loss of active ingredients. In order to minimize it, the vacuum freeze-drying method is most suitable.

Therefore, the cooked silkworm product of the present invention may be hot air dried or vacuum freeze dried.

The powdering may be performed using any method such as a household mixer, hammer mill, roller mill, air jet mill (freeze grinding), but in order to minimize sample loss, prevent component distortion, and finely powder, a roller mill method is preferred. good night. Normally, it is very difficult to grind powder particles to a size of less than 0.1 mm when pulverized with a household blender or hammer mill. On the other hand, when pulverized repeatedly with a roller mill several times, the powdered particles can be finely pulverized to an average size of 10 μm. and products are expected to have a favorable effect.

In addition, after being prepared in the powder form, the cooked silkworm processed product powder may be prepared in the form of an extract, and at this time, it may be prepared by extracting with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof. The lower alcohol having 1 to 4 carbon atoms may be selected from the group consisting of methanol, ethanol, propanol, isopropanol, butanol and isobutanol. The water, lower alcohol having 1 to 4 carbon atoms, or a mixed solution thereof may be used in a volume of 1 to 40 times (1 to 40 liters based on 1 kg) based on the weight of the cooked sleep powder, preferably 5 to 40 times the volume. can The extraction condition of the extract may be 1 to 48 hours at 20 to 100 ° C, and the process may be repeated 1 to 4 times.

Another method is to add water to an extract obtained by extracting and concentrating the cooked silkworm processed powder with water, a lower alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof, and then suspending the powder, preferably by weight of 1 to 4% of the weight of the extract. After suspension by adding 1000 times, more preferably 1 to 500 times, and most preferably 1 to 50 times of water, a solvent selected from the group consisting of hexane, chloroform, ethyl acetate, and butanol is added to the suspension. It can be prepared from the fraction obtained by adding

The preparation temperature of the extract or its fraction may be 20 to 100 ℃, but is not limited thereto. The extraction or fractionation time is not particularly limited, but it is preferable to extract within 10 minutes to 2 days, and as a device for extraction, a conventional extraction device, an ultrasonic crusher or a fractionator may be used. The solvent may be removed from the extract or fraction thus prepared by hot air drying, vacuum drying or lyophilization. In addition, the extract or fraction may be used after being purified using column chromatography. The chromatography is silica gel column chromatography, LH-20 column chromatography, ion exchange resin chromatography, medium pressure liquid chromatography chromatography), thin layer chromatography (TLC), silica gel vacuum liquid chromatography, and high performance liquid chromatography.

In the present invention, the silkworm breed of the cooked silkworm product may be at least one selected from the group consisting of white dog breed, yellow dog breed, green dog breed, and red dog breed, and as long as the antisarcomenia effect desired by the present invention is exerted, the cooked silkworm As the silkworm breed of the processed product, any breed of silkworm known in the art may be used.

Antisarcopenia refers to one or more effects selected from the group consisting of weight gain, muscle weight increase, muscle strength increase, exercise ability improvement, postural control ability improvement, spatial memory improvement, social memory increase, and muscle degradation gene expression inhibition, This may have an effect of improving sarcopenia, in particular, geriatric sarcopenia.

As long as the object of the present invention can be achieved, the muscle degradation gene may also include any gene known in the art, and preferably, myostatin, artrogin-1 ), it may be one or more genes selected from the group consisting of MuRF1 (Muscle RING-finger protein-1) and FoxO3 (Forhead box O3), but is not limited thereto.

That is, in the present invention, as a result of administering the processed silkworm product of the present invention to an animal artificially induced sarcopenia and analyzing the effect on the disease, muscle characteristics such as weight, muscle weight, grip strength, etc. and it was confirmed that the expression of a gene that destroys muscle protein (muscle degradation gene) was reduced.

As such, in the present invention, a novel sarcopenia preventive or therapeutic effect of the cooked silkworm product of the present invention was identified, and this effect was not known at all until now, and was identified for the first time by the present inventors.

In the pharmaceutical composition of the present invention, the cooked silkworm product may be added in an amount of 0.001 to 100% by weight to the pharmaceutical composition of the present invention. The pharmaceutical composition may be formulated and used in the form of oral formulations such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, external preparations, suppositories and sterile injection solutions according to conventional methods, respectively.

The pharmaceutical composition of the present invention may further include at least one selected from the group consisting of pharmaceutically acceptable carriers, excipients and diluents.

Carriers, excipients, and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, saccharin, Monkroside, stevia, starch, and acacia. rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. can When formulated, it is prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., and these solid preparations include at least one excipient in the composition of the present invention, for example, starch, calcium carbonate, sucrose or lactose, It is prepared by mixing gelatin, etc. In addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral use include suspensions, solutions for oral use, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included. . Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspensions. As a base for the suppository, witepsol, macrogol, tween 61, cacao butter, laurin paper, glycerogeratin and the like may be used.

The dosage of the pharmaceutical composition of the present invention will vary depending on the age, sex, and weight of the subject to be treated, the specific disease or pathological condition to be treated, the severity of the disease or pathological condition, the route of administration, and the judgment of the prescriber. Determination of dosage based on these factors is within the level of those skilled in the art, and generally dosages range from 0.01 mg/kg/day to approximately 2000 mg/kg/day. A more preferred dosage is 1 mg/kg/day to 500 mg/kg/day. Administration may be administered once a day, or may be administered in several divided doses. The dosage is not intended to limit the scope of the present invention in any way.

Subjects receiving the pharmaceutical composition of the present invention include all mammals such as rats, livestock, humans, etc., but are not limited thereto as long as the desired effect is exerted in the administered subject.

In addition, the pharmaceutical composition of the present invention can be administered by various routes. All modes of administration are contemplated, eg oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine intrathecal or intracerebrovascular injection. Since the composition of the present invention has little toxicity and side effects, it is a drug that can be safely used even when taken for a long period of time for preventive purposes.

At this time, the cooked silkworm product is an effective amount to exhibit the desired efficacy of the present invention, and preferably contains 0.01 to 100% by weight, more preferably 0.1 to 90% by weight, based on the total weight of the composition in terms of powder weight. It is good to contain %.

In addition, according to another aspect of the present invention, the present invention provides a food composition for preventing and improving sarcopenia, comprising the cooked silkworm product as an active ingredient.

The food composition includes compositions for all types of food such as health functional food, nutritional supplements, food additives, special medicinal food and dietary supplements do.

The cooked silkworm processed product containing the silk protein of the present invention exhibits an effect of inhibiting muscle loss or enhancing muscle strength (improving muscle function), so it is useful, for example, as a health functional food for suppressing aging in the elderly or for promoting growth of growth layers. can be used At the same time, it can be used as a special medicinal food for patients suffering from sarcopenia.

At this time, the cooked silkworm product may be used in an amount of 0.01 to 100% by weight in the food composition of the present invention. Food compositions of this type can be prepared in various forms according to conventional methods known in the art. For example, as a health food, it can be manufactured in the form of chewing gum, vitamin complex, tea, juice, and drink containing cooked silkworm processed products containing silk protein, and foods containing cooked silkworm processed products containing silk protein as an active ingredient. The composition may be ingested by granulating, encapsulating, or powdering. The functional food composition of the present invention may include components commonly added during food preparation, and may include, for example, proteins, carbohydrates, fats, nutrients, and seasonings. For example, when prepared as a drink, citric acid, high fructose corn syrup, sugar, glucose, acetic acid, malic acid, fruit juice, jujube extract, licorice extract, etc. may be further included in addition to the cooked silkworm processed product containing the silk protein of the present invention.

The food composition includes various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and enhancers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids , a protective colloidal thickener, a pH adjusting agent, a stabilizer, a preservative, glycerin, alcohol, a carbonating agent used in carbonated beverages, and the like. In addition, it may contain extracts for the production of natural fruit juice, fruit juice beverages and vegetable beverages. These components may be used independently or in combination.

In addition, according to another aspect of the present invention, the present invention is a feed additive for preventing or improving sarcopenia in animals containing a silk protein-containing cooked silkworm product or a feed for preventing or improving sarcopenia in animals containing the same composition is provided.

The cooked silkworm product containing the silk protein may be prepared in the same way as the pharmaceutical composition or food composition.

The cooked silkworm product containing the silk protein of the present invention exhibits an overall muscle strength increase effect due to inhibition of muscle loss or improvement of muscle function, so it can be included in a feed composition as a growth promoter for animals or livestock.

Specifically, the feed containing the silkworm protein-containing cooked silkworm product according to the present invention as an active ingredient can be prepared with various types of feed known in the art, and preferably includes concentrated feed, roughage feed, or special feed. .

Concentrated feed includes seeds and fruits including grains such as wheat, oats, and corn, bran including rice bran, wheat bran, and barley bran as by-products obtained after refining grains, soybeans, fluids, sesame seeds, linseed, and coco palm oil. Fish soluble, which is a condensed fresh liquid obtained from fish meal, fish meal, fish meal, fish meal, fish meal, fish meal, fish meal, fish meal, fish meal soluble), meat meal, blood meal, feather meal, skim milk powder, animal feed such as dried whey, yeast, chlorella, seaweed, etc.

Forages include raw grass feed such as wild grass, grass, green cutting, turnip for feed, beet for feed, root vegetables such as Lutherbearer, a type of turnip, raw grass, green cut crops, grains, etc. These include silage, grasses, hay from cut and dried grasses, straw from breeding crops, and leaves from leguminous plants.

Special feeds include mineral feeds such as shells and rock salt, urea feeds such as urea or its derivative, diureide isobutane, and ingredients that are likely to be lacking when only natural feed ingredients are mixed, or in trace amounts in formulated feeds to improve the storage life of feeds. There are feed additives, dietary supplements, etc.

The feed composition according to the present invention may include various feed additives.

In the present invention, the term "feed additive" is a substance added to feed for various effects, such as supplementation of nutrients and prevention of weight loss, improvement of digestibility of fiber in feed, improvement of oil quality, prevention of reproductive disorder and improvement of conception rate, and prevention of high temperature stress in summer. say The feed additive of the present invention corresponds to supplementary feed under the Feed Management Act, and is a mineral preparation such as sodium bicarbonate (sodium bicarbonate), bentonite, magnesium oxide, and complex minerals, and minerals such as zinc, copper, cobalt, and selenium, which are trace minerals. preparations, vitamins such as kerotene, vitamin E, vitamins A, D, E, nicotinic acid, and vitamin B complex, protective amino acids such as methionine and lysic acid, protective fatty acids such as calcium salts of fatty acids, probiotics (lactic acid bacteria), yeast culture Water, live bacteria such as fungal fermentation, yeast, and the like may be further included.

The feed composition according to the present invention is not particularly limited as long as it is an individual for the purpose of increasing overall muscle strength and promoting growth due to inhibition of muscle loss or improvement of muscle function, and any one can be applied. The subject may include animals such as non-primates (eg cows, pigs, horses, cats, dogs, rats and mice) and primates (eg monkeys such as cynomolgous monkeys and chimpanzees). The subject is a livestock animal (eg, horse, cow, pig, etc.) or a pet animal (eg, dog or cat).

The dosage of the feed composition according to the present invention will depend on a number of factors such as the species, size, weight and age of the animal. In principle, a typical dosage may range from 0.001 to 10 g per animal/day, but is not limited thereto.

In addition, according to another aspect of the present invention, there is provided a method for treating sarcopenia comprising the step of administering a composition comprising the silk protein-containing cooked silkworm product to a non-human subject.

The term "individual" of the present invention may include, without limitation, mammals, farmed fish, etc., including mice, livestock, humans, etc., which are likely or have developed sarcopenia.

The administration route of the pharmaceutical composition for the treatment of sarcopenia of the present invention may be administered through any general route as long as it can reach the target tissue. The pharmaceutical composition of the present invention is not particularly limited thereto, but depending on the purpose, intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, intranasal administration, intrapulmonary administration, intrarectal administration, etc. can be administered through However, since the cooked silkworm product containing the silk protein may be denatured by gastric acid during oral administration, the oral composition should be formulated so that the active agent is coated or protected from degradation in the stomach. In addition, the composition may be administered by any device capable of transporting an active substance to a target cell.

Since the method of the present invention includes the above-described cooked silkworm products containing silk protein as an active ingredient, redundant descriptions are omitted to avoid excessive complexity in the present specification.

Overall, the present invention has been identified for the first time that the intake of cooked sleep, a new type of raw material for food and medicine, can effectively suppress muscle loss and at the same time increase weight gain excellently, It is expected that suppressive health supplements or medicines will be developed and marketed, thereby greatly highlighting the value of a deep sleep to many people suffering from various diseases caused by sarcopenia. In addition, it is expected that the effect of contributing to the development of the sericulture industry and agriculture by creating utilization and high added value of cooked sleep is expected to be great.

The cooked silkworm product containing silk protein according to the present invention is effective in weight gain, muscle strength improvement, muscle weight increase and/or memory improvement in a sarcopenia model, and is therefore used as a composition for preventing, treating, and improving sarcopenia. can be utilized In addition, it is expected that various health supplements or medicines will be developed and marketed using the active ingredients of the present invention, which will contribute to the development of the sericulture industry by creating utilization of cooked silkworm products with silk thread and adding high value. It is expected to greatly contribute to reducing soaring social costs (health care costs, etc.) and improving the quality of life of the people due to sarcopenia and various adult diseases caused by it.

Figure 1 shows the results of comparison of body weight changes in the general feed-intake SAMP8 sarcopenia model (Nf) and the golden silk red jam feed-intake SAMP8 sarcopenia model (GS-HJf).
Figure 2 shows the results of comparing spatial memory changes in the normal feed-intake SAMP8 sarcopenia model (Nf) and the golden silk red jam feed-intake SAMP8 sarcopenia model (GS-HJf).
Figure 3 shows the results of comparing the change in exercise capacity in the general feed SAMP8 sarcopenia model (Nf) and the golden silk red jam feed intake SAMP8 sarcopenia model (GS-HJf).
Figure 4 shows the results of comparison of muscle strength changes in the general feed intake SAMP8 sarcopenia model (Nf) and golden silk red jam feed intake SAMP8 sarcopenia model (GS-HJf).
Figure 5 shows the results of comparison of muscle weight changes in the general feed SAMP8 sarcopenia model (Nf) and the golden silk red jam feed SAMP8 sarcopenia model (GS-HJf).
Figure 6 shows changes in the expression of muscle generation-related genes and muscle breakdown-related genes expressed in muscles in the general feed intake SAMP8 sarcopenia model (Nf) and golden silk red jam feed intake SAMP8 sarcopenia model (GS-HJf) in muscle Shows the comparison result.
Figure 7 shows the results of comparison of body weight changes in the general feed intake DEX-induced sarcopenia model (Nf) and various red jam feed intake DEX-induced sarcopenia models (HJf). As a positive control group, a DEX-induced sarcopenia model in which creatine was ingested was used.
Figure 8 shows the results of comparison of muscle weight changes in the normal feed intake DEX-induced sarcopenia model (Nf) and the red jam feed intake DEX-induced sarcopenia model (HJf).
Figure 9 shows the results of comparing spatial memory changes in the normal feed intake DEX-induced sarcopenia model (Nf) and the red jam feed intake DEX-induced sarcopenia model (HJf).
Figure 10 shows the results of comparing the change in postural control ability in the normal feed intake DEX-induced sarcopenia model (Nf) and the red jam feed intake DEX-induced sarcopenia model (HJf).
Figure 11 shows the results of comparison of muscle strength changes in the normal feed intake DEX-induced sarcopenia model (Nf) and the red jam feed intake DEX-induced sarcopenia model (HJf).
Figure 12 shows the results of comparison of changes in social memory in the normal feed intake DEX-induced sarcopenia model (Nf) and the red jam feed intake DEX-induced sarcopenia model (HJf).

Hereinafter, the present invention will be described in more detail through examples. These examples are only for illustrating the present invention, and it will be apparent to those skilled in the art that the scope of the present invention is not to be construed as being limited by these examples.

Example 1. Preparation of cooked silkworm freeze-dried powder containing silk protein (cooked silkworm product; Hongjam)

The present inventors bred silkworms and cooked mature silkworms for 2 hours in 100 ° C steam after 5th instar 4th day to prepare a cooked silkworm processed product, freeze-dried the cooked silkworm processed product after rapid freezing, and steamed mature silkworm freeze-dried powder (steamed mature silkworm) powder; Hongjam) was prepared.

Silkworms commonly used for medicinal purposes were 5th instar 3rd silkworms, and 5th instar 4th silkworms were considered inedible silkworms. As silkworms pass through the 5th instar and 3rd day, the silk glands become enlarged, and after the 7th or 8th day of the 5th instar, the internal organs degenerate and become a sleeper containing only the enlarged silk glands in the body.

Although silk protein is produced in the body of the silkworm from the 3rd day of the 5th instar, the silkworm at this time has little silk protein, and the silk protein was stored in the body of the silkworm for the first time when the silkworm reached the 4th day of the 5th instar. As this rapidly increases, body tissue becomes much larger and harder than silkworms of 5 instars and 3 days of the previous day.

Therefore, the silkworm used in the present invention further includes rapidly growing silk threads in the body of the silkworm from the 5 instar 4 day 4 sleep silkworm to the deep sleep period along with the body of the silkworm.

On the other hand, as a result of the component analysis, it was confirmed that the content of various components in the ripe sleep was changed in various ways as the cooked sleep became.

In particular, it can be seen that the content of serine, glycine, and alanine significantly increased in the content of crude protein, and it can be confirmed that the pharmacological effect of the cooked sleep will also change due to the change in the components of the cooked sleep.

Example 2. Demonstration of anti-sarcoma effect according to hongjam intake in SAMP8 sarcopenia model

In order to demonstrate the anti-sarcoma effect of Hongjam prepared in Example 1, the present inventors used the SAMP8 (Senescence-accelerated mouse P-8) sarcopenia model, which is a representative mammalian model used in the study of various geriatric diseases including sarcopenia. Using , changes in weight, muscle strength, spatial memory, and motor skills were confirmed.

Briefly, it is as follows:

Twenty SAMP8 rats that consumed Hongjam were divided into two groups, and fed normal food (Nf) or HongJam food (0.5 g/Kg body weight HongJam food, HJf) from 4 weeks to 56 weeks, respectively, and their body weight, Changes in muscle strength, spatial memory and motor skills were confirmed.

Body weight was measured using a precision balance once a week.

Spatial memory was measured using Y-maze.

Exercise capacity was measured by a wheel running test using an activity wheel (Jeung Do Bio & Plant Co. LTD).

Muscle strength was measured from 34 weeks to 57 weeks at 4-week intervals using a grip strength tester.

2-1. Confirmation of weight gain in red jam intake SAMP8 sarcopenia model

As a result of confirming the body weight level in the red jam intake SAMP8 sarcopenia model, as shown in Figure 1, the body weight of the red jam intake SAMP8 sarcopenia model rat was heavier than that of the normal feed intake SAMP8.

It was confirmed that the weight of the SAMP8 sarcopenia model rats, which had no difference until 4 weeks, was significantly heavier than the weight of the SAMP8 sarcopenia rats fed the normal diet from 18 weeks later. It was confirmed that the difference in body weight of SAMP8 sarcopenia mice was due to the difference in feed. Depending on the age, the SAMP8 model rats ingesting hongjam showed a tendency to increase their weight up to 30 weeks and then maintain their body weight. On the other hand, the SAMP8 model rats fed the normal diet showed a tendency to increase their body weight up to 17 weeks and then maintain it or decrease it after 50 weeks. The greatest difference in body weight was at 56 weeks after birth, and the body weight of SAMP8 sarcopenia model rats consuming red jam food was 4.976 g heavier than that of normal diet fed SAMP8 sarcopenia model rats.

In addition, as a result of measuring the body weight of SAMP8 sarcopenia model rats that consumed normal feed or red jam diet starting from 4 weeks after birth to 56 weeks, the body weight of SAMP8 rats fed red jam feed was higher than that of SAMP8 rats fed normal feed. Statistically significant increase (F _{(1, 529)} = 228.2058, p = 1.47 x 10 ^-41 ). Over time, the body weight of the SAMP8 sarcopenia model rats fed the normal diet or the red jam diet changed (F _{(52, 529)} = 126.0829, p = 1.72 x 10 ^-52 ). Time did not affect the difference in body weight according to the difference in feed (F _{(52, 529)} = 11.15529, p = 0.248)

That is, it shows that Hongjam of the present invention is effective for weight gain and maintenance in sarcopenia.

2-2. Confirmation of Spatial Memory Enhancement in SAMP8 Sarcopenia Model with Hongjam Intake

In the case of the elderly, spatial memory tends to decrease, and it is known that the SAMP8 sarcopenia model rat also has abnormalities in memory.

As a result of confirming the level of spatial memory in this red jam intake SAMP8 sarcopenia model, as shown in FIG. When confirmed using this method, in the case of consumption of red jam feed, excellent spatial memory was shown from 36 weeks to 56 weeks.

In addition, the deterioration of spatial memory observed in SAMP8 sarcopenia model rats fed normal feed was not observed in SAMP8 sarcopenia model rats fed red jam diet. As a result of measuring the change in spontaneous alteration rate at 4-week intervals from 36 to 56 weeks, deterioration of spatial memory was observed in SAMP8 sarcopenia model rats fed normal food, but not observed in SAMP8 sarcopenia model rats fed red jam food.

(Two-way ANOVA analysis: Nf vs HJf; F _{(1, 49)} = 14.83315, p = 4.15 x 10 ^-4 , Within, weeks; F _{(4, 49)} = 3.887955, p = 9.26 x 10 ^-3 , Between -within interaction; F _{(4, 49)} = 0.484623, p = 0.747)

That is, it shows that Hongjam of the present invention is effective in enhancing spatial memory in sarcopenia.

2-3. Confirmation of improvement in exercise capacity in the SAMP8 sarcopenia model with hongjam intake

As a result of performing a wheel running test to confirm the exercise capacity of the SAMP8 sarcopenia model rats, as shown in Figure 3, the exercise capacity of the SAMP8 sarcopenia model rats consuming red jam feed is superior to that of the SAMP8 sarcopenia model rats consuming normal feed. confirmed. At 46 weeks and 50 weeks, the SAMP8 sarcopenia model rats fed the normal diet were able to rotate the wheel at 13.6 and 19.6 times per minute, whereas the SAMP8 sarcopenia model rats fed the red jam diet achieved 40.2 and 44.4 times per minute. could rotate

On the other hand, at 54 weeks after the onset of sarcopenia, the SAMP8 sarcopenia model mice fed the normal diet could rotate the wheel 4 times per minute, but the SAMP8 sarcopenia model mice fed the red jam could rotate the wheel 20.2 times per minute.

That is, it was confirmed that the deterioration of exercise capacity observed in SAMP8 sarcopenia model rats fed a normal diet did not appear in SAMP8 sarcopenia model rats fed a red jam diet. From 46 weeks to 54 weeks, the exercise capacity of SAMP8 sarcopenia model rats fed red jam was statistically significantly superior to that of normal feed fed SAMP8 sarcopenia model rats.

(Two-way ANOVA analysis: Between, Nf vs HJf; F _{(1, 29)} = 20.32269, p = 1.45 x 10 ^-4 , within, weeks; F _{(2, 29)} = 5.701859, p = 9.42 x 10 ^-3 , between-within interaction; F _{(4, 49)} = 0.412168, p = 0.667)

The above results show that hongjam intake prevents loss of motor ability caused by sarcopenia.

2-4. Confirmation of improvement in muscle strength in the SAMP8 sarcopenia model with Hongjam intake

In order to confirm the change in muscle strength in the SAMP8 sarcopenia model rat, a grip strength test was performed at 4-week intervals from week 34 to week 57, as shown in FIG. 4, compared to SAMP8 sarcopenia model rats fed general feed It was confirmed that the muscle strength of SAMP8 sarcopenia model rats ingesting red jam feed was always strong. At 34 weeks, the muscle strength of the SAMP8 sarcopenia model rats fed the red jam diet was 32.6% stronger than that of the rats fed the normal diet, 25.4% at 37 weeks, 6.8% at 41 weeks, 4.3% at 45 weeks, 12.7% at 49 weeks, and 53 weeks. 9.0% at 57 weeks and 13.7% at 57 weeks, it was consistently statistically significantly stronger.

(Two-way ANOVA analysis result: normal diet vs red jam diet: F _{(1, 59)} = 17.50181, p = 0.000121, weeks: F _{(5, 59)} = 7.429776, p = 3.15 x 10 ^-5 , within-between interactioin : F _{(5, 59)} = 0.293668, p = 0.91412)

2-5. Confirmation of muscle weight increase in red jam intake SAMP8 sarcopenia model

As a result of comparing the weight change of the muscle weight of the 57-week-old red jam intake SAMP8 sarcopenia model rat and the normal feed intake SAMP8 sarcopenia model rat muscle weight, as shown in Figure 5, Quadriceps, Gastrocnemius, Tibialis anterior in the left and right hind limbs When the weight was measured after extraction, it was confirmed that the muscles of the SAMP8 sarcopenia model rats fed the general diet were statistically significantly less in weight than the muscles of the SAMP8 sarcopenia model rats fed the red jam diet. There was a statistically significant difference in weight between the muscles.

That is, the weight of the muscles of the model rats that consumed Hongjam was statistically significantly heavier. Both the right and left hind limbs were the same, and there was a significant difference in the weight of the muscles between the Red Jam diet group and the general diet group.

(Two-way ANOVA analysis: muscles from the left hind leg: Between, Nf vs HJf ; F _{(1, 39)} = 13.708375, p = 6.4 x 10 ^-6 , within, muscles ; F _{(3, 39)} = 12.358885, p = 1.34 x 10 ^-3 , between-within interaction; F _{(3, 39)} = _1.4223519 , p = 0.254. the right hind leg: Between, Nf vs HJf ; 10 ^-6 , within, muscles ; F _{(3, 39)} = 17.013083, p = 2.46 x 10 ^-4 , between-within interaction; F _{(3, 39)} = 1.2981033, p = 0.292).

2-6. Confirmation of decreased expression of muscle degradation-related gene markers in the red jam intake SAMP8 sarcopenia model

The purpose of this study was to compare the expression changes of myogenic genes and muscle degradation genes expressed in the muscles of 57-week-old red jam-fed SAMP8 sarcopenia model rats and normal feed-fed SAMP8 sarcopenia model rats.

At this time, total RNA was obtained from the muscle tissues extracted from each mouse to synthesize cDNA, and each gene was amplified from the synthesized cDNA using a PCR method, and the changes in their expression levels were compared.

As a result, as shown in FIG. 6, the expression of myogenic differentiation 1 (MyoD) and myogenic factor 5 (Myf5), which are myogenic transcription factors, and myogenin and myogenic factor-6 (Myf-6), which are myogenic regulators, were significantly different between the two groups. there was no difference in

However, on the other hand, as muscle degradation genes (markers), muscle specific ubiquitin ligase MURF1 (muscle RING finger-1) and Astrogin-1; In the case of FoxO3 (Forhead box O3) and Myostatin, which enhance the expression of muscle disintegration genes, it was confirmed that the intake of red jam significantly decreased in the muscles of SAMP8 sarcopenia rats.

The above results prove that intake of Hongjam inhibits muscle protein degradation.

Example 3. Proof of prevention of sarcopenia by ingestion of hongjam in drug-induced sarcopenia model

In order to demonstrate that Hongjam prepared in Example 1 exhibits an anti-sarcopenia effect against drug-induced sarcopenia, the present inventors used a DEX-induced sarcopenia model, which is a sarcopenia-induced drug model, to determine weight, Muscle weight, muscle strength, postural control ability, spatial memory and social memory levels were checked.

Briefly, it is as follows:

60 C57BL/6J rats were divided into 6 groups, and regular feed (Nf) and 0.5 g/Kg body weight or 1.0 g/Kg body weight Golden-Silk HongJam food (GS) and 0.5 g/Kg orange Orange-Silk HongJam (OS) feed, 0.5 g/Kg White-Jade HongJam (WJ) feed, and 0.6 g/Kg creatine (Creatine monohydrate) feed were consumed. Creatine was used as a positive control as a food additive known to reduce fatigue during exercise and increase muscle mass and testosterone. After mixing Dexamethasone (DEX), a drug known to induce sarcopenia in rats that consumed the feed for 6 weeks, with PEG400, intraperitoneal injection (IP) to C57BL/6J rats for 10 days at a rate of 25mg/Kg ) was performed.

The weight change was continuously measured, and after the experiment was completed, the muscle was removed and the weight was measured.

As for muscle strength, a grip strength test was performed before and after DEX-IP to measure changes in muscle strength.

Clasping assay was performed before and after DEX-IP to measure changes in self-control ability.

Changes in spatial memory were measured using Y-maze before and after DEX-IP.

3-1. Confirmation of weight gain in red jam intake DEX-induced sarcopenia model

As a result of comparing the weight change according to the diet of the DEX-induced sarcopenia model rats, as shown in FIG. 7, DEX-induced sarcopenia C57BL/6J mice and creatine feed intake DEX-induced muscle When the body weight change of sarcopenic C57BL/6J rats was measured, the weight of DEX-induced sarcopenia rats fed with 0.5 g/Kg golden silk hongjam diet tended to be heavier than that of other 0.5g/Kg hongjam diet intake groups or the control group. Could know. It was confirmed that these weight gain and weight maintenance effects after DEX-IP appeared more clearly in DEX-induced sarcopenia model rats consuming 1.0 g/Kg golden silk feed.

{Two-way ANOVA, Between foods [F(5, 840) = 137.1483, p = 2.7 x 10-106], Within Days [F(19, 840) = 35.50741, p = 5.69 x 10-94], Between/ Within [F(95, 840) = 0.979774, p = 0.536773]}.

This result shows that even in DEX-induced sarcopenia model rats, as in the SAMP8 genetic sarcopenia model rats, Golden Silk hongjam had the most excellent weight maintenance effect, and 1.0 g/Kg Golden Silk hongjam intake was more reliable than 0.5 g/Kg. It can be seen that there is a maintenance effect.

3-2. Confirmation of muscle weight increase in red jam intake DEX-induced sarcopenia model

After sacrificing DEX-induced sarcopenia C57BL/6J mice fed general feed or various red jam feeds at 91 days after birth, the quadriceps of the hind legs were removed and weight changes were compared. As shown in FIG. 8, 0.5 g golden It was confirmed that the weight of the hind leg quadriceps of the group consuming silk red jam feed (GS 0.5 g) and 1.0 g golden silk red jam feed (GS 1.0 g) increased by 8.44% and 12.28%, respectively, compared to the hind quadriceps of the normal feed (Nf) group. did The hind limb quadriceps weights of the 0.5 g white jade japonica diet (WJ) and 0.5 g orange jacaranda red jam diet (OS) were only 99.08% and 95.85% less than those of the Nf group. And the hind limb quadriceps weight of the creatine-fed group was only 95.95%.

This result shows that the muscle weight of the rats that consumed Golden Silk Redjam was heavier than that of the normal feed group.

3-3. Confirmation of spatial memory enhancement effect in DEX-induced sarcopenia model of hongjam intake

As a result of confirming the spatial memory enhancement effect in the DEX-induced sarcopenia model in which general feed or various red jam feed was consumed using Y-maze, as shown in FIG. 9, Dexamethasone intraperitoneal injection in the case of the general feed (Nf) intake group. After (DEX-IP), it was confirmed that spatial memory decreased by -7.6702%. On the other hand, it was confirmed that spatial memory decline did not occur after DEX-IP in the various red jam intake groups compared to the general feed intake group. Among them, in the case of the 0.5g or 1.0g Golden Silk Redjam feed group (GS 0.5g, GS 1.0g), spatial memory increased by 11.96761% and 12.93875%, respectively. In the case of orange jam red jam feed intake group (OS), spatial memory increased by 8.670652% and 8.501939%, respectively. In addition, the positive control group, the creatine-fed group, also showed an increase in spatial memory of 10.61603%.

This result shows that the golden silk hongjam intake group showed the most excellent spatial memory enhancement effect.

3-4. Confirmation of postural control ability increase effect in DEX-induced sarcopenia model

As a result of confirming the effect of increasing postural control ability in the DEX-induced sarcopenia model ingesting general feed or various red jam feeds using the Limb clasping test, as shown in FIG. 10, in the case of the general feed (Nf) intake group, Dexamethasone intraperitoneal After injection (DEX-IP), the postural control ability value deteriorated by 0.75. However, in the case of the 0.5g or 1.0g golden silk red jam feed intake group, it was confirmed that the values deteriorated by 0.55 and 0.2 after DEX-IP, respectively, and recovered by 27.70% and 73.40% compared to the general feed. In addition, in the case of the white jade and red jam feed intake group (WJ) or the orange japonica red jam feed (OS) intake group, the values deteriorated after DEX-IP were 0.6 and 0.05, respectively, which were 20.00% and 93.40% compared to the general feed intake group, respectively. confirmed to have recovered. And in the case of the creatine feed intake group, it was confirmed that the value deteriorated after DEX-IP was 0.2, which was 73.40% recovery compared to the general feed intake group.

This result shows that red jam feed has an overall postural control ability recovery effect.

3-5. Confirmation of muscle strength increase effect in DEX-induced sarcopenia model

As a result of confirming the effect of increasing muscle strength in the DEX-induced sarcopenia model ingesting general feed or various red jam feeds using a grip strength test, as shown in FIG. 11, in the case of the general feed (Nf) intake group, Dexamethasone intraperitoneal injection ( After DEX-IP), it decreased by -0.20013 N. In contrast, only -0.05333 N and -0.03237 N were decreased in the group consuming 0.5 g or 1.0 ha of golden silk red jam feed, respectively.

And only -0.05007 N and -0.02287 N were decreased in the white jade jam red jam feed intake group and the orange jam red jam feed intake group, respectively. In contrast, the creatine feed intake group decreased -0.1966 N similarly to the general feed intake group.

This result shows that intake of red jam feed can prevent muscle strength loss induced by DEX.

3-6. Confirmation of social memory enhancement effect in DEX-induced sarcopenia model of hongjam intake

As a result of confirming the effect of increasing social memory in the DEX-induced sarcopenia model in which general feed or various red jam feeds were consumed by performing Social interaction assay, as shown in FIG. 12, in the case of the general feed (Nf) intake group, Dexamethasone intraperitoneal injection After (DEX-IP), social memory decreased by -20.5178%, but there was no decrease in social memory in the various red jam feed and creatine intake groups. The 0.5g or 1.0g golden silk red jam feed intake group had a change of -0.69906% and -0.83705%, respectively, and the white jade red jam feed intake group and orange red jam feed intake group had a change of -0.95935% and 3.314759%, respectively. there was And the creatine feed intake group had a change of 0.770995%.

This result shows that the social memory damaged by DEX-IP is prevented when golden silk red jam feed is consumed.

Overall, Hongjam showed excellent effects on weight gain, muscle strength improvement, muscle weight increase, memory improvement, and muscle decomposition gene suppression effect in sarcopenia models showing severe weight loss and muscle strength abnormalities. These results show that consumption of hongjam can prevent and treat the onset of sarcopenia.

Based on the above experimental results, as a composition for preventing and treating sarcopenia containing silk protein-containing processed silkworm as an active ingredient is provided, it is possible to provide natural materials for health functional foods or pharmaceuticals for sarcopenia. As a result, it is expected to make a great contribution to improving public health and reducing health care costs.

The present invention has been examined with a focus on preferred embodiments, and those skilled in the art can implement embodiments of a different form from the detailed description of the present invention within the essential technical scope of the present invention. You will be able to. Here, the essential technical scope of the present invention is shown in the claims, and all differences within the equivalent range should be construed as being included in the present invention.

<Formulation Example 1. Pharmaceutical formulation>

200 g of cooked silkworm product powder (Hongjam) containing silk protein of Example 1 was mixed with 175.9 g of lactose, 180 g of potato starch, and 32 g of colloidal silicic acid. After adding 10% gelatin solution to this mixture, it was pulverized and passed through a 14 mesh sieve. It was dried and the mixture obtained by adding 160 g of potato starch, 50 g of talc and 5 g of magnesium stearate was made into tablets.

<Formulation Example 2. Food Manufacturing>

Formulation Example 2-1. Preparation of seasoning for cooking

A cooking seasoning for health promotion was prepared by adding 1% by weight of the cooked silkworm product powder containing the silk protein of Example 1 to the cooking seasoning.

Formulation example 2-2. Manufacture of Flour Food

The cooked silkworm product powder containing the silk protein of Example 1 was added to wheat flour at 0.1% by weight, and bread, cakes, cookies, crackers, and noodles were prepared using the mixture to prepare health-promoting foods.

Formulation Example 2-3. Preparation of soups and gravies

The cooked silkworm product powder containing the silk protein of Example 1 was added to the soup and broth in an amount of 0.1% by weight to prepare soup and broth for health promotion.

Formulation Example 2-4. Manufacture of dairy products

The cooked silkworm processed product powder containing the silk protein of Example 1 was added to milk in an amount of 0.1% by weight, and various dairy products such as butter and ice cream were prepared using the milk.

Formulation Example 2-5. vegetable juice manufacturing

Vegetable juice for health promotion was prepared by adding 0.5% by weight of silkworm processed product powder having silk protein of Example 1 to tomato juice or carrot juice.

Formulation Example 2-6. fruit juice manufacturing

Fruit juice for health promotion was prepared by adding 0.1% by weight of apple juice or grape juice to silkworm processed powder having silk protein of Example 1.

Claims (14)

A pharmaceutical composition for the prevention or treatment of sarcopenia comprising a silk protein-containing processed silkworm product as an active ingredient.
According to claim 1,
Characterized in that the sarcopenia is senile sarcopenia,
A pharmaceutical composition for preventing or treating sarcopenia.
According to claim 1,
Characterized in that the sarcopenia is at least one selected from the group consisting of muscular dystrophy, myasthenia gravis, muscular dystrophy, myasthenia, hypotonia, muscle weakness, muscular dystrophy, amyotrophic lateral sclerosis and myasthenia gravis,
A pharmaceutical composition for preventing or treating sarcopenia.
According to claim 1,
The composition exhibits one or more effects selected from the group consisting of weight gain, muscle weight increase, muscle strength increase, exercise capacity enhancement, posture control ability enhancement, spatial memory enhancement, social memory enhancement, and muscle degradation gene expression inhibition. characterized by,
A pharmaceutical composition for preventing or treating sarcopenia.
According to claim 4,
The muscle degradation gene is one or more genes selected from the group consisting of Myostatin, Atrogin-1, MuRF1 (Muscle RING-finger protein-1) and FoxO3 (Forhead box O3) characterized in that,
A pharmaceutical composition for preventing or treating sarcopenia.
According to claim 1,
The cooked silkworm product is cooked by putting raw silkworms having silk protein selected from silkworms from 5 instar 4 day silkworms to sleeping silkworms in water for 30 minutes to 24 hours at a temperature of 55 to 125 ° C. Characterized in that it is prepared by cooking with heat,
A pharmaceutical composition for preventing or treating sarcopenia.
According to claim 6,
Characterized in that the cooked silkworm product is hot air dried or vacuum freeze-dried,
A pharmaceutical composition for preventing or treating sarcopenia.
According to claim 1,
Characterized in that the cooked silkworm product is an extract extracted with water, alcohol having 1 to 4 carbon atoms or a mixed solvent thereof,
A pharmaceutical composition for preventing or treating sarcopenia.
According to claim 1,
Characterized in that the composition further comprises at least one selected from the group consisting of pharmaceutically acceptable carriers, excipients and diluents,
A pharmaceutical composition for preventing or treating sarcopenia.
A food composition for preventing or improving sarcopenia, comprising a processed silkworm protein-containing cooked silkworm product.
A health functional food for preventing or improving sarcopenia, including a processed silkworm product containing silk protein.
A feed additive for preventing or improving sarcopenia in animals, comprising a processed silkworm product containing silk protein.
A feed composition for preventing or improving sarcopenia in animals comprising the feed additive of claim 12.
A method for treating sarcopenia comprising the step of administering to a non-human subject a composition comprising a silkworm protein-containing processed silkworm product.

Images